Our Science – Gu Website
Shuo Gu, Ph.D.
Shuo Gu received his B.A. in Tsinghua University, CHINA in 1998. He completed his Ph.D. training in the laboratory of Dr. John Rossi at Beckman Research Institute, City of Hope, Los Angeles. Shuo Gu undertook his postdoctoral training in the laboratory of Dr. Mark Kay at Stanford University Medical School, Palo Alto. Both his Ph.D. and postdoctoral research focused on the mechanisms of RNA interference and microRNA pathways, and their applications in gene therapy. He Joined the Gene Regulation and Chromosome Biology Laboratory in 2013.
Research in the Gu lab aims to unveil the roles of non-coding RNAs in gene regulation and develop new therapeutic approaches for cancer treatment. MicroRNA (miRNA), as a small non-coding RNA, plays essential roles in gene regulation networks, human diseases and cancer. We are interested in understanding the mechanisms of miRNA biogenesis, post-transcriptional modifications, and biological functions in mammalian systems. This information will then be used to test novel RNA-based approaches designed to alter gene expression with improved safety, off-targeting, and potency profiles, which can then be used as tools for biological discovery and therapeutics.
Fidelity of miRNA biogenesis
Enormous efforts have focused on studying the alteration in miRNA expression levels during development and disease. However, imprecise biogenesis or post-maturation modification alters miRNA function by changing the sequence of the final product rather than its abundance. The biological importance of these changes in normal and disease states is not well defined. We are interested in unveiling the molecular mechanism controlling the fidelity of miRNA biogenesis and its effects on miRNA function. Recent advances in sequencing technology are making it possible to reveal such information in living cells. Together with applying classical biochemical approaches and reporter based functional assays, we established a “loop-counting” rule governing the preciseness of Dicer processing which is critical for miRNA biogenesis and function. We will extend our efforts to study other events in miRNA biogenesis to develop a more complete picture of how the ends of miRNA are generated, which can then serve as a reference point in investigating post-maturation modification of miRNAs.
In vivo study of RISC assembly
MicroRNAs and siRNAs interact with target sequences, inducing gene repression through the RNA-induced silencing complex (RISC) that consists of one of four mammalian Argonaute (Ago) proteins. Despite its importance, our understanding of RISC assembly is limited. The majority of the knowledge about this process is drawn from experiments performed within cell-free or reconstituted systems. During the past few years, we have developed a cell based assay to specifically measure the RISC assembly process of cleaving Ago (Ago2) and non-cleaving Agos (Ago1/3/4) in vivo. Applying such system, we are interested in studying how miRNA isoforms, which are generated by non-precise processing during biogenesis, affect RISC assembly and function in normal and disease states.
Novel design of potent DNA-directed RNAi (shRNA) with minimal off-target effects
DNA-directed RNAi (shRNA expressed from plasmids) is more desirable than traditional synthetic siRNAs in many applications. It is preferred or required in genetic screens and specific RNAi approaches in gene therapy settings. However, the application of ddRNAi is hampered due to unwanted off-target effects. Currently, attempts in reducing off-target effects are mainly based on empirical approaches with limited success. We are interested in achieving such goal through rational design based on the knowledge gained in the mechanistic studies outline above. Our finding on Dicer processing has established the loop-counting rule, which laid the ground work in designing Pol III driven pre-miRNA-like shRNAs free of off-target effects resulted from heterogeneous processing. We are currently working on transferring such design into Pol II system. In addition, based on the recent findings of how RISC interacts with its target mRNA on molecular level, we are developing a novel strategy for designing shRNA with minimal off-target effects originated from miRNA-like pathway.
This page was last updated on 12/31/2013.